atrial peptides
TRANSCRIPT
![Page 1: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/1.jpg)
1
![Page 2: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/2.jpg)
2
![Page 3: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/3.jpg)
INTRODUCTION
• They are protein hormones secreted by heart musclecells.• Powerful vasodilator.• Involved in homeostatic control of body water, Na+,K+
and fat.• Released by atrial myocytes in response to high bloodpressure.• ANP acts to reduce water, Na+, adipose loads oncirculatory system, thereby reducing blood pressure.
3
![Page 4: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/4.jpg)
STRUCTURE
•ANP is a 28 amino acid peptide with a 17 amino acid ring in the middle of themolecule.•The ring is formed by a disulfide bond between 2 cysteine residues at positions7 and 23.•ANP is closely related to BNP and CNP which all share the same amino acidring.
4
![Page 5: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/5.jpg)
PRODUCTION
• Produced, stored and released by cardiac myocytes of atria of heart.•Released in response to atrial stretch and a variety of other signals induced byhypervolemia, exercise or caloric restriction.• Expressed in ventricle in response to stress induced by increased afterload orinjury.
5
![Page 6: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/6.jpg)
SECRETED IN RESPONSE TO-
Atrial distension
Sympathetic stimulation of β adrenoceptors
Raised sodium concentration
Angiotensin-II
Endothelin, a powerful vasoconstrictor
6
![Page 7: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/7.jpg)
RECEPTORS
GC-A
•Also known as NPRA/ANPA or NPR1
GC-B
•Also known as NPRB/ANPB or NPR2
Natriuretic peptide clearance receptor (NPRC)
•ANPC or NPR3
7
![Page 8: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/8.jpg)
PHARMACOLOGICAL EFFECTS
RECEPTOR BINDING
REDUCES BLOOD
VOLUME
REDUCES CARDIAC
OUTPUT AND BP
• Lipolysis is increased and renal sodium reabsorption is decreased
• Overall effect is to counter the increase in blood pressure and volume caused byrenin- angiotensin system
8
![Page 9: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/9.jpg)
1. RENAL
•Dilates afferent glomerular arteriole.•Constricts efferent glomerular arteriole.•Increases pressure in glomerular capillaries, increasing GFR, resulting in greater excretion of sodium and water.•Decreases sodium reabsorption in DCT and collecting duct•Inhibits renin secretion.•Reduces aldosterone secretion.
9
![Page 10: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/10.jpg)
2. VASCULAR
Relaxes vascular smooth muscle in arterioles and venules by-1. Membrane receptor mediated elevation of vascular smooth
muscle cGMP2. Inhibition of effect of catecholamine
10
![Page 11: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/11.jpg)
•Increases release of free fatty acids from adipose tissue•Plasma concentration of glycerol and non esterified fatty acids are increased by IV infusion of ANP
3. ADIPOSE TISSUE
11
![Page 12: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/12.jpg)
• Inhibits maladaptive cardiac hypertrophy
• Mice lacking cardiac NPRA develop increased cardiac mass and severe fibrosis and die suddenly
4. CARDIAC
12
![Page 13: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/13.jpg)
• Reduces aldosterone secretion by the zonaglomerulosa of adrenal cortex.
13
5. ADRENAL
![Page 14: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/14.jpg)
• ANP and related peptides are used as biomarkers for cardiovascular diseases such as stroke, MI, coronary artery disease and heart failure.
14
BIOMARKER
![Page 15: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/15.jpg)
• Recombinant human ANP has been approved in Japan to treat patients with heart failure.
15
THERAPEUTIC USE
![Page 16: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/16.jpg)
• Regulation of effects of ANP is achieved through gradual degradation of peptide by the enzyme neutral endopeptidase (NEP).
• NEP inhibitors have been developed but not yet been licensed. They maybe clinically useful in treating congestive heart failure.
DEGRADATION
16
![Page 17: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/17.jpg)
• www.wikipedia.com
• www.google.com
• www.ncbi.nlm.nih.gov
• www.cvpharmacology.com
• www.sciencedirect.com
REFERENCES
17
![Page 18: Atrial peptides](https://reader031.vdocuments.net/reader031/viewer/2022021923/5a6d3c577f8b9ac2418b58e3/html5/thumbnails/18.jpg)
18